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Abstract 
Use of implantable cardioverter defibrillator (ICD) in primary prevention has been shown to reduce the risk 
of death among patients with severe left ventricular systolic dysfunction (LVSD) due to ischaemic 
cardiomyopathy. However, among patients with heart failure (HF) and severe LVSD who do not have 
coronary artery disease, the evidence of ICD benefit is less robust. As a matter of fact data supporting the 
use of ICD in such patients are limited to few randomized controlled clinical trials that included a small 
number of patients, subgroup analysis of larger trials or meta-analysis. Recently, in the Danish Study to 
Assess the Efficacy of ICDs in Patients with Non-Ischemic Systolic Heart Failure on Mortality (DANISH) trial, 
which included 1116 patients with symptomatic nonischaemic HF and severe LVSD, ICD therapy did not 
show a significant reduction of the overall mortality primary endpoint raising doubts about its use in this 
category of patients.  Low mortality rates and use of a better background HF treatment as compared with 
prior trials may partly explain the results of the DANISH Study. Anyway, these findings underline the 
importance of careful selection of candidates receiving an ICD for sudden cardiac death primary 
prevention. 
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Text. 
According to the World Health Organization sudden cardiac death (SCD) is defined as a natural, non-
traumatic, unexpected death characterized by a sudden loss of consciousness and subsequent decease 
within one hour of symptoms onset 1. This temporal limit is conventionally extended to 24 hours when 
death occurs unwitnessed 1. It has been estimated that 30 to 50% of SCDs occur in patients with known 
severe LVSD independently from underlying aetiology (ischaemic vs. nonischaemic) 2,3. Among patients with 
HF and severe LVSD, the percentage of deaths attributable to SCD is higher in subjects with less severe 
degree of symptoms (64% in NYHA functional class II patients enrolled in the MERIT-HF trial) and decreases 
with the worsening of HF (33% in NYHA functional class IV patients enrolled in the MERIT-HF trial) 4. 
Ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) degenerating in VF are the commonest 
malignant arrhythmias causing SCD in patients with HF or dilated cardiomyopathy and severe LVSD. 
However, the occurrence of pathological bradiarrhythmias and of pulseless electrical activity can determine 
SCD in a significant proportion of patients with advanced HF 5. From a pathophysiological standpoint, the 
occurrence of SCD in patients with HF and severe LVSD can be explained by the three determinants of 
arrhythmogenesis proposed by Philippe Coumel at the end of the last century 6. The presence of 
remodelled, often hypertrophied myocardial tissue, mixed with fibrotic area of varying extension may act 
as substrate for the onset of arrhythmic events under the effect of pro-arrhythmic triggers such as 
premature ventricular contractions (isolated or repetitive), electrolyte abnormalities and haemodynamic 
and/or ischaemic disorders which are extremely frequent in this category of patients. Moreover, the 
imbalance between the sympathetic and parasympathetic nervous systems (with the hyperactivation of the 
first and the suppression of the latter) may negatively modulate these interactions further facilitating the 
onset of malignant and life-threatening arrhythmic events (Figure 1). 
The use of antiarrhythmic drugs for SCD prevention in patients with HF and severe LVSD is of limited utility. 
Several studies have demonstrated that class I antiarrhythmic drugs can increase mortality whereas class III 
antiarrhythmic drugs, although safe, are no effective in reducing the risk of death. Therefore, the 
implantable cardioverter defibrillator (ICD), which was developed in the seventies by Mirowski and Mower 
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and tested in human for the first time in February 1980, has progressively become established for SCD 
prevention among patients with HF and LVSD. The small size of modern ICDs makes the subcutaneous, 
subclavicular implant of such devices, including one or more transvenous leads, feasible and relatively safe. 
Besides antibradycardia pacing, the ICD can detect and treat malignant tachyarrhythmias by means of 
overdrive pacing, electrical cardioversion and defibrillation. Initially, the impact of ICD on mortality has 
been shown in randomized controlled clinical trials enrolling SCD survivors (secondary prevention trials) 
and comparing the clinical efficacy of ICD with antiarrhythmic drugs (e.g. Antiarrhythmics Versus 
Implantable Defibrillators [AVID], Cardiac Arrest Survivor Hamburg [CASH] and the Canadian Implantable 
Defibrillator Study [CIDS])7. The vast majority of patients enrolled in these studies had an underlying 
ischaemic cardiomyopathy. More recently, randomized controlled clinical trials enrolled patients without 
prior ventricular arrhythmias deemed at risk for SCD because of severe LVSD and symptoms of HF (primary 
prevention trials). Several studies like the Multicenter Automatic Defibrillator Implantation Trial (MADIT-I), 
the Multicenter Unsustained Tachycardia Trial (MUSTT) and the Multicenter Automatic Defibrillator 
Implantation Trial II (MADIT-II)  have shown the efficacy of ICD in reducing all-cause mortality among 
patients with previous myocardial infarction and severe LVSD demonstrating a relative risk reduction 
ranging from 28% to 59% 8. Although patients with nonischaemic cardiomyopathy carry an annual SCD risk 
of 4% 9, the efficacy of ICD for SCD primary prevention seems inferior in these patients as compared with 
those with an underlying ischaemic cardiomyopathy 10.  
Five prospective randomized controlled clinical trials have tested the use of ICD in primary prevention of 
SCD among patients with nonischaemic cardiomyopathy so far (main features of these studies are 
summarized in Table 1). The first studies which included approximately 200 patients with nonischaemic 
cardiomyopathy (i.e. the Cardiomyopathy Trial [CAT] and the Amiodarone Versus Implantable Cardioverter 
Defibrillator Trial [AMIOVIRT]) did not show significant benefit for ICD therapy on the primary endpoint of 
all-cause mortality 11,12. Until 2016, the larger prospective randomized study exclusively enrolling patients 
with nonischaemic cardiomyopathy  was the Defibrillator in Non-Ischemic Cardiomyopathy Treatment 
Evaluation (DEFINITE) Trial which randomized 458 patients with severe LVSD (i.e. left ventricular ejection 
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fraction 35%) and prior nonsustained ventricular tachycardia to ICD implantation and medical therapy vs. 
optimized medical therapy (approximately 85% of patients were taking an ACE-inhibitor and a beta-blocker) 
13. Over a mean follow-up of 2.5 years there was a trend toward reduction in the primary endpoint of all-
cause mortality in patients treated with ICD (two years all-cause mortality 8% vs. 14% in ICD recipients and 
patients treated with optimal medical therapy respectively, p=0.08). 
Other data in support of the use of ICD for primary prevention of SCD among patients with nonischaemic 
cardiomyopathy derive from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) which enrolled 
patients with both ischaemic (52%) and nonischaemic (48%) cardiomyopathy and severe LVSD 14. The 
design feature of this trial envisaged three-arms randomization: placebo group vs. amiodarone group vs. 
ICD group. During a median follow-up of 45.5 months, amiodarone therapy showed no survival benefit over 
placebo (HR = 1.06, 97.5% CI 0.86-1.30, p = 0.53) whereas a significant reduction was observed in patients 
receiving an ICD (HR = 0.77, 97.5% CI 0.62-0.96, p = 0.007) with a significant absolute risk reduction of 7.2% 
as compared with control. As a pre-specified subgroup analysis the benefit of ICD was tested in patients 
with nonischaemic cardiomyopathy separately: all-cause mortality reduction was similar to that observed in 
the overall study although not reaching statistical significance (HR = 0.73, 97.5% CI 0.50 – 1.07, p =0.06). 
On the basis of these data the recent guidelines on diagnosis and treatment of patients with HF issued by 
the European Society of Cardiology suggest ICD therapy for primary prevention of SCD in symptomatic 
(functional class NYHA II-III) patients with nonischaemic cardiomyopathy, severe LVSD (i.e. left ventricular 
ejection fraction 35%) despite ≥ three months of optimal medical therapy with a Class I recommendation, 
level of evidence B (whereas for patients with ischaemic cardiomyopathy the level of evidence is A) 15. 
However, these recommendations should be revisited in the light of the new findings from the Danish 
Study to Assess the Efficacy of ICDs in Patients with Non-Ischemic Systolic Heart Failure on Mortality 
(DANISH) which were presented at the Congress of the European Society of Cardiology in August 2016 16. 
This study enrolled 1116 patients with symptomatic HF and severe LVSD (i.e. left ventricular ejection 
fraction 35%) not caused by ischaemic heart disease (which was ruled out in the vast majority of patients 
5 
 
by means of coronary angiography, coronary CT or single-photon emission CT). Demonstration of 
ventricular premature contractions at the time of enrolment or history of nonsustained ventricular 
tachycardia, which have an uncertain and inconstant prognostic impact (see Figure 2), were not amongst 
the inclusion criteria in contrast to prior studies (i.e. AMIOVIRT and DEFINITE). Patients were randomized 
1:1 to ICD with guideline-directed optimal medical therapy or medical therapy alone. There were no 
significant differences between the two study arms at the time of randomization and both groups were 
optimally treated from a pharmacological (97% of patients were on an ACE-inhibitor or an ARB, 92% on a 
beta-blocker and 58% on a mineralcorticoid receptor antagonist) and non-pharmacological (58% of patients 
had a cardiac resynchronization therapy device) standpoint. Over a median follow-up of 5.6 years, there 
were no significant differences in the primary endpoint of all-cause mortality between ICD recipients and 
the control group (120 deaths [21.6%] vs. 131 deaths [23.4%] in the ICD and in the control group 
respectively, HR = 0.87, 95% CI 0.68 – 1.12, p = 0.28, 1.8% absolute risk reduction). Similarly, taking into 
account the secondary endpoint of cardiovascular mortality, there were no significant differences between 
the two arms (77 deaths [13.8%] vs. 95 deaths [17.0%], HR 0.77, 95% CI 0.57 – 1.05, p = 0.10, 3.2% absolute 
risk reduction) whereas a significant reduction in SCD occurrence was observed among ICD recipients as 
compared with control group (24 SCDs [4.3%] vs. 46 SCDs [8.2%], HR 0.50, 95% CI 0.31-0.82, p = 0.005, 3.9% 
absolute risk reduction). Subgroup analysis did not show significant differences in the primary outcome 
across pre-specified subgroups with the exception of age. More in detail, among patients aged 68 years or 
less receiving an ICD, a significant reduction in all-cause mortality was observed as compared with the 
control group (HR = 0.64, 95% CI 0.45-0.90). When interpreting the findings from the DANISH study a few 
remarks must be made: 1) compared with prior primary prevention ICD trials, observed mortality rates 
were significantly lower, possibly reflecting the improvements in HF medical therapy and the extensive use 
of cardiac resynchronization therapy which was not available when older primary prevention trials were 
conducted; in addition, the results from DANISH study suggest that patients with HF due to nonischaemic 
causes receiving optimized therapy have a much better prognosis than commonly perceived; 
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2) considering that the event rates was lower than expected, it is likely that the DANISH sample size was 
insufficient to demonstrate an ICD benefit on overall mortality; however, patients enrolled in clinical trials 
are usually younger and have less comorbidities as compared with patients encountered in everyday 
clinical practice: therefore the risk of death for cardiovascular vs. noncardiovascular causes (on which the 
ICD has no effect) is greater in the context of a clinical trial possibly favouring an overestimation of ICD 
efficacy; 3) whenever an ICD is indicated for primary prevention, the existence of competing causes of 
death should always be considered, especially among the elderly; in other words, both frailty and the high 
number of comorbidities typical of such group of patients might increase the risk of death for 
noncardiovascular causes hampering ICD efficacy. 
The findings of the DANISH trial have been recently included in a meta-analysis that grouped all the studies 
testing ICD efficacy in SCD primary prevention among patients with HF and nonischaemic aetiology 17. 
Overall, among the 2970 patients included, ICD was associated with a significant all-cause mortality relative 
risk reduction as compared with medical therapy (HR = 0.76, 95% CI 0.62-0.94). The authors of the same 
study, by combining the results of the DANISH trial and of the  Comparison of Medical Therapy, Pacing, and 
Defibrillation in Heart Failure (COMPANION) Study18, speculated on the hypothesis that  ICD may be 
effective in reducing mortality among candidates to cardiac resynchronization therapy. 
In conclusion, the recent findings from the DANISH trial underline the importance of accurate selection of 
ICD candidates in the setting of SCD primary prevention and question current knowledge and beliefs. 
Selection of patients for ICD therapy should be based on careful weighting of expected advantages and 
potential risks bearing in mind that, in primary prevention of SCD, elderly and nonischaemic patients may 
benefit less than other patients. Guidelines recommendations should be revised in the light of these new 
pivotal observations. 
  
7 
 
Figure 1 
 
The arrhythmogenesis triangle proposed by Coumel is useful to describe the main pathophysiological mechanisms involved in sudden cardiac 
death among patients with heart failure. SCD = sudden cardiac death, LV = left ventricle, PVC = premature ventricular contraction, VT = ventricular 
tachycardia. 
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Figure 2 
 
Nonsustained ventricular arrhythmias can have a different prognostic impact among patients with heart failure. Premature ventricular 
contractions, especially if isolated and monomorphic, together with slow nonsustained ventricular tachycardia of short duration are usually benign 
(green light); short coupling nonsustained ventricular tachycardia of longer duration and with shorter cycle length may be potentially dangerous 
(yellow light); rapid, polymorphic nonsustained ventricular tachycardia are always malignant (red light). 
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Table 1.  Randomized controlled clinical trials testing ICD therapy for SCD primary prevention among patients with nonischaemic cardiomyopathy. 
 CAT AMIOVIRT DEFINITE SCD-HeFT DANISH 
Publication year 2002 2003 2004 2005 2016 
Number of patients enrolled 104 103 458 2521 1116 
% pts with nonischaemic CMP 100% 100% 100% 48% 100% 
Mean age (SD)/median (IQR) 52 (11) 59 (11) 58 (20 – 84)* 60 (51 – 68) 64 (56 – 72) 
Mean EF (SD)/median (IQR) 24 (7) 23 (9) 21 (7 – 35)* 25 (20 – 30) 25 (20 – 30) 
Comorbidities 
- Hypertension 
- Diabetes 
 
- 
- 
 
65 (63%) 
35 (34%) 
 
- 
105 (23%) 
 
1400 (55%) 
767 (30%) 
 
348 (31%) 
211 (19%) 
All-cause mortality 
Control vs. ICD 
HR (95% CI) 
 
2 (4%) vs. 4 (8%)° 
- 
 
7 (14%) vs. 6 (12%) 
- 
 
40 (14%) vs. 28 (8%) 
HR 0.65 (0.40 – 1.06) 
 
244 (29%) vs. 182 (22%) 
HR 0.77 (0.62 – 0.96) 
 
131 (23%) vs. 120 (22%) 
HR 0.87 (0.68 – 1.12) 
Cardiovascular mortality 
Control vs. ICD 
HR (95% CI) 
 
1 (2%) vs 4 (8%)° 
- 
 
5 (10%) vs. 4 (8%) 
- 
 
26 (11%) vs. 12 (5%) 
- 
 
167 (20%) vs. 122 (15%)  
HR 0.76 (0.60 – 0.95) 
 
95 (17%) vs. 77 (14%) 
HR 0.77 (0.57 – 1.05) 
Mortality due to SCD 
Control vs. ICD 
HR (95% CI) 
 
0 vs. 0° 
- 
 
2 (4%) vs. 1 (2%) 
- 
 
14 (6%) vs. 3 (1%) 
HR 0.20 (0.06 – 0.71) 
 
37 (5%) vs. 95 (11%) 
HR 0.40 (0.27 – 0.59) 
 
46 (8%) vs. 24 (4%) 
HR 0.50 (0.31 – 0.82) 
 
Legend: CMP = cardiomyopathy, EF = ejection fraction, HR = hazard ratio, CI = confidence interval, SD = standard deviation, IQR = interquartile range, ° = 1 year Follow-up,  
* = Range min - max 
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